Merck & Co. Inc. (MRK)

Oncology Corporate Profile

Stock Performance

63.5000
-0.4100

HQ Location

One Merck Drive
Whitehouse Station, NJ 08889

Company Description

Merck is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

Website: http://www.merck.com

Brand Generic Indication
Emend®aprepitantEMEND, in combination with other antiemetic agents, is indicated for the:
• prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin
• prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (see DOSAGE AND ADMINISTRATION).
EMEND is indicated for the prevention of postoperative nausea and vomiting (see DOSAGE AND ADMINISTRATION).
Gardasil®human papillomavirus quadrivalentGARDASIL is a vaccine indicated in girls and women 9-26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18:
• Cervical cancer
• Genital warts (condyloma acuminata)
and the following precancerous or dysplastic lesions:
• Cervical adenocarcinoma in situ (AIS)
• Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3
• Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
• Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3
• Cervical intraepithelial neoplasia (CIN) grade 1
INTRON® A Injectioninterferon alfa-2b recombinantHairy Cell Leukemia INTRON A is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia.

Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but
at high risk for systemic recurrence, within 56 days of surgery.

Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically aggressive (see Clinical Experience) follicular Non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.

Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION). The use of this product in adolescents has not been studied.

AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune system as indicated by total CD4 count.

Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. Studies in these patients demonstrated that INTRON A therapy can produce clinically meaningful effects on this disease, manifested by normalization of serum alanine aminotransferase (ALT) and reduction in liver necrosis and degeneration.

A liver biopsy should be performed to establish the diagnosis of chronic hepatitis. Patients should be tested for the presence of antibody to HCV. Patients with other causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior to initiation of INTRON A therapy, the physician should establish that the patient has compensated liver disease. The following patient entrance criteria for compensated liver disease were used in the clinical studies and should be considered before INTRON A treatment of patients with chronic hepatitis C:

• No history of hepatic encephalopathy, variceal bleeding, ascites, or other
clinical signs of decompensation
• Bilirubin ?2 mg/dL
• Albumin Stable and within normal limits
• Prothrombin Time <3 seconds prolonged
• WBC ?3000/mm3
• Platelets ?70,000/mm3

Serum creatinine should be normal or near normal. Prior to initiation of INTRON A therapy, CBC and platelet counts should be evaluated in order to establish baselines for monitoring potential toxicity. These tests should be repeated at weeks 1 and 2 following initiation of INTRON A therapy and montly thereafter. Serum ALT should be evaluated at approximately 3-month intervals to assess response to treatment (see DOSAGE AND ADMINISTRATION).

Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating hormone (TSH) levels can be maintained in the normal range by medication. TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH testing should be repeated at 3 and 6-months (see PRECAUTIONS - Laboratory Tests).

INTRON A in combination with REBETOL is indicated for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon therapy and in patients 18 years of age and older who have relapsed following alpha interferon therapy. See REBETOL package insert for additional information.

Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in patients 1 year of age or older with compensated liver disease. Patients who have been serum HBsAg positive for at least 6-months and have evidence of HBV replication (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies in these patients demonstrated that INTRON A therapy can produce virologic remission of this disease (loss of serum HBeAg), and normalization of serum aminotransferases. INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.

Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be performed to establish the presence of chronic hepatitis and the extent of liver damage. The physician should establish that the patient has compensated liver disease. The following patient entrance criteria for compensated liver disease were used in the clinical studies and should be considered before INTRON A treatment of patients with chronic hepatitis B:

• No history of hepatic encephalopathy, variceal bleeding, ascites, or other
signs of clinical decompensation
• Bilirubin Normal
• Albumin Stable and within normal limits
• Prothrombin Time Adults <3 seconds prolonged
Pediatrics ?2 seconds prolonged
• WBC ?4000/mm3
• Platelets Adults ?100,000/mm3
Pediatrics ?150,000/mm3

Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic hepatitis C should not be treated with INTRON A. CBC and platelet counts should be evaluated prior to initiation of INTRON A therapy in order to establish baselines for monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2, 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin and bilirubin, should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy, since patients may become virologic responders during the 6-month period following the end of treatment. In clinical studies in adults, 39% (15/38) of responding patients lost HBeAg 1 to 6-months following the end of INTRON A therapy. Of responding patients who lost HBsAg, 58% (7/12) did so 1-to-6-months posttreatment.

A transient increase in ALT ?2 times baseline value (flare) can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and pediatrics, elevations in bilirubin ?3 mg/dL (?2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical symptomatology and liver function tests including ALT, prothrombin time, alkaline phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week intervals (see WARNINGS).
Keytruda® pembrolizumabKEYTRUDA is a programmed death receptor-1 (PD-1)- blocking antibody indicated for the treatment of:

•for the first-line treatment of patients with unresectable or metastatic melanoma regardless of BRAF status

•for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor

•patients with unresectable or metastatic melanoma.

•patients with metastatic NSCLC whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy.

Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.


Temodar®temozolomideTEMODAR Capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.

TEMODAR Capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma, ie, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
Zolinza™vorinostatZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for:
• Treatment of cutaneous manifestations in patients with cutaneous Tcell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
dinaciclib / MK7965CDK inhibitorChronic Lymphocytic Leukemia (CLL)IIILigand
vintafolide / EC145vinca alkaloidPlatinum-sensitive Ovarian cancerIII
ridaforolimus / AP23573/MK-8669mTOR inhibitorSoft tissue or bone sarcomaIIIAriad
Keytruda? / pembrolizumab (+pemetrexed)monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)IIIEli Lilly
Temodar? / temozolomidealkylating agent2nd line metastatic GliomaIII
Temodar? / temozolomidealkylating agentBrain metastases from Non Small Cell Lung Cancer (NSCLC)III
Temodar? / temozolomidealkylating agentLow grade GliomaIII
Temodar? / temozolomidealkylating agentPediatric refractory Brain cancerIII
MK-2206AKT inhibitor1st line metastatic Colorectal cancerII
Sym004anti-EGFR monoclonal antibody 1st line metastatic Colorectal cancerIISymphogen
lambrolizumab / MK-3475 anti-PD1 antibody2nd line metastatic Melanoma II
ridaforolimus / AP23573/MK-8669mTOR inhibitorBreast cancerIIAriad
MSB0010718CAnti-PD-L1 antibodyBreast cancerII
MK-3475anti-PD1 antibodyMelanomaII
dalotuzumab / MK-0646anti-IGF-1R monoclonal antibody (humanized)Non Small Cell Lung Cancer (NSCLC)II
ridaforolimus / AP23573/MK-8669mTOR inhibitorNon Small Cell Lung Cancer (NSCLC)IIAriad
Sym004anti-EGFR monoclonal antibody Squamous cell carcinoma of Head & NeckIISymphogen
robatumumabanti-IGF-1R monoclonal antibodyVarious cancer typesII
MK-0457aurora kinase inhibitorVarious cancer typesII
odanacatib / MK-0822cathepsin K inhibitorVarious cancer typesII
Unnamedcell cycle inhibitorVarious cancer typesII
Unnamedcell cycle inhibitorVarious cancer typesII
Keytruda? / pembrolizumabmonoclonal antibodyBladder cancerII
Keytruda? / pembrolizumabmonoclonal antibodyBladder cancerII
Keytruda? / pembrolizumab (+ DNX-2401)oncolytic virusGlioblastoma Multiforme (GBM)IIDNAtrix
Temodar? / temozolomidealkylating agent1st line metastatic MelanomaII
Temodar? / temozolomidealkylating agentAcute Myelogenous Leukemia (AML)II
Temodar? / temozolomidealkylating agentEwing's SarcomaII
Temodar? / temozolomidealkylating agentMyelodysplastic Syndrome (MDS)II
Temodar? / temozolomidealkylating agentNon-Hodgkin's Lymphoma (NHL)II
Zolinza? / vorinostatHDAC inhibitor1st line metastatic Breast cancer II
dalotuzumab / MK-0646anti-IGF-1R monoclonal antibody (humanized)1st line metastatic Colorectal cancerI
SCH 900776cell cycle inhibitorAcute Lymphocytic Leukemia (ALL)I
SCH 900776cell cycle inhibitorAcute Myelogenous Leukemia (AML)I
MK-2206AKT inhibitorBreast cancerI
lambrolizumab / MK-3475 anti-PD1 antibodyNon Small Cell Lung Cancer (NSCLC)I
lambrolizumab / MK-3475 anti-PD1 antibodyVarious cancer typesI
dalotuzumab / MK-0646anti-IGF-1R monoclonal antibody (humanized)Various cancer typesI
MK-4721anti-PSCA monoclonal antibody (humanized)Various cancer typesI
MK-2461c-Met kinase inhibitorVarious cancer typesI
V930immunotherapy (targets cancers expressing HER2 and/or CEA)Various cancer typesI
ridaforolimus / AP23573/MK-8669mTOR inhibitorVarious cancer typesIAriad
MK-0752notch signaling pathway inhibitorVarious cancer typesI
MSB0010718CAnti-PD-L1 antibodyVarious cancer typesI
Keytruda? / pembrolizumabmonoclonal antibodyBreast cancerI
Keytruda? / pembrolizumab (+ margetuximab)monoclonal antibodyGastric cancerIMacroGenics
Keytruda? / pembrolizumabmonoclonal antibodyGastric cancerI
Keytruda? / pembrolizumabmonoclonal antibodyHead & Neck cancerI
Keytruda? / pembrolizumabmonoclonal antibodyRenal cell carcinoma (RCC)I
pembrolizumab (+ ID-G100)immunotherapyMelanomaImmune Design
pembrolizumab (+ LV 305)immunotherapyMelanomaImmune Design
pembrolizumab (+ ID-G100) / ID-G100 (+ pembrolizumab)immunotherapyNon-Hodgkin's Lymphoma (NHL)Immune Design
pembrolizumab (+ LV 305)immunotherapyNon-Hodgkin's Lymphoma (NHL)Immune Design
Keytruda? / pembrolizumab (+ entinostat)monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)Syndax

View additional information on product candidates here »

Source


http://www.merck.com

Recent News Headlines

Merck Partners with American Cancer Society to Address Cancer in Women

11/1/2016 11:22 am

(Merck) Nov 1, 2016 - Merck, a leading science and technology company, and the American Cancer Society (ACS) today released a report that shows all four of the top causes of cancer deaths in women worldwide are mostly preventable or can often be detected early, when treatment is more successful.

NICE Rejects Merck’s Erbitux

11/1/2016 11:18 am

(PharmaTimes [UK]) Nov 1, 2016 - The National Institute for Health and Care Excellence has decided that use of Merck's head and neck cancer drug Erbitux is not cost-effective for the NHS in England and Wales.

Merck Wins Early U.S. Approval for Keytruda in Untreated Lung Cancer

10/25/2016 12:24 pm

(Reuters) Oct 25, 2016 - Merck & Co has won U.S. approval to market its immunotherapy Keytruda for use in previously untreated lung cancer patients two months ahead of schedule, making it the only such drug cleared for first-line treatment.

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

10/21/2016 07:04 am

(Merck) Oct 21, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).

Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint

10/19/2016 11:16 am

(Yahoo! Finance) Oct 19, 2016 - Merck & Co., Inc., known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint.

Merck Statement on FDA Approval of 2-Dose Regimen of GARDASIL® 9 for Girls and Boys 9 through 14 Years of Age

10/13/2016 11:47 am

(Merck) Oct 7, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a 2-dose vaccination regimen for GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), for use in girls and boys 9 through 14 years of age.

Transgene Links With Merck, Pfizer For Head And Neck Cancer Trial

10/12/2016 11:28 am

(PharmaTimes [UK]) Oct 12, 2016 - Transgene has entered into collaboration agreement with Merck KGaA and Pfizer under which it will sponsor an early-stage study testing a potential new combination treatment for head and neck cancer.

Bristol Lung-Cancer Setback Puts Rival Merck Drug In Driver Seat

10/11/2016 11:42 am

(Reuters) Oct 11, 2016 - New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday.

New Data on the Combination of Lilly's ALIMTA(R) (pemetrexed) and Merck's KEYTRUDA(R) (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer

10/10/2016 10:15 am

(Lilly) Oct 9, 2016 - Data released from KEYNOTE-021, Cohort G, which evaluated ALIMTA® (pemetrexed) plus carboplatin in combination with Merck's KEYTRUDA® (pembrolizumab) in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC), showed that the combination of ALIMTA, KEYTRUDA and carboplatin demonstrated superior efficacy compared to ALIMTA and carboplatin - standard of care - alone.

Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress

10/10/2016 09:50 am

(Merck) Oct 8, 2016 - Data comparing KEYTRUDA to chemotherapy shows continued benefit with follow-up beyond 2.5 years in patients with ipilimumab-refractory advanced melanoma.

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients

10/10/2016 09:48 am

(Merck) Oct 9, 2016 - KEYNOTE-024, published in The New England Journal of Medicine, showed KEYTRUDA as monotherapy demonstrated superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with high levels of PD-L1 expression; KEYNOTE-021, Cohort G, published in The Lancet Oncology, showed KEYTRUDA in combination with chemotherapy demonstrated superior efficacy compared to chemotherapy alone as first-line treatment; trial enrolled patients regardless of PD-L1 expression.

Merck's Keytruda Achieves 24 Percent Response In Bladder Cancer Study

10/10/2016 09:45 am

(Reuters) Oct 8, 2016 - Merck & Co's immunotherapy Keytruda proved effective as an initial treatment for nearly a quarter of patients with advanced bladder cancer too frail for standard cisplatin chemotherapy, according to interim results from a study presented on Saturday.

Merck Solidifies Lung Cancer Immunotherapy Lead Over Bristol-Myers Squibb

10/10/2016 09:42 am

(TheStreet) Oct 9, 2016 - Merck's Keytruda works in first-line lung cancer, Bristol's Opdivo does not.

Study May Boost Use of Merck Lung-Cancer Drug

10/10/2016 06:25 am

(Morningstar/Dow Jones Business News) Oct 9, 2016 - Patients with advanced lung cancer who took Merck & Co.’s immune-boosting drug Keytruda as their first treatment lived longer on average than those who received chemotherapy in a new study that could herald a big shift in treatment of the deadliest cancer.

Two New Trials of Merck's KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016

9/28/2016 11:59 am

(Merck) Sept 28, 2016 - Merck, known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA® (pembrolizumab), the company's anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11.

Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push

9/23/2016 11:11 am

(NASDAQ/Dow Jones Business News) Sept 23, 2016 - Merck & Co.'s immunotherapy cancer drug Keytruda is finding its way into China as the first imported drug approved for use under a pilot program on the resort island of Hainan intended to boost medical tourism.

Roche Says New MS Drug Works Better Than Merck's Rebif

9/14/2016 12:05 pm

(Reuters) Sept 14, 2016 - Roche said on Wednesday its Ocrevus multiple sclerosis drug controlled the most common form of the disease better than a rival's medicine and worked against another form of MS for which there is no approved treatment.

FDA to Review Merck’s Keytruda as First-Line Treatment for Lung Cancer

9/7/2016 12:17 pm

(NASDAQ/Dow Jones Business News) Sept 7, 2016 - The U.S. Food and Drug Administration will review Merck & Co.’s immunotherapy cancer drug Keytruda as a first-line treatment for patients with the most common form of lung cancer, the company said Wednesday.

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

9/7/2016 07:02 am

(Merck) Sept 7, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016.

Merck Scraps Development Of Osteoporosis Drug Due To Stroke Risk

9/2/2016 10:15 am

(Reuters) Sept 2, 2016 - Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.

Lung Cancer Doctors Eye Merck's Keytruda Over Bristol's Opdivo

8/26/2016 07:07 am

(Reuters) Aug 25, 2016 - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

8/24/2016 12:11 pm

(Yahoo! Finance) Aug 24, 2016 - Biothera Pharmaceuticals, Inc. today announced a collaboration with Merck, known as MSD outside the United States and Canada, to expand the companies’ ongoing clinical program evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 inhibitor, in combination with Biothera’s Imprime PGG, a Pathogen Associated Molecular Patterning molecule, or PAMP.

Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors

8/23/2016 11:32 am

(TheStreet) Aug 23, 2016 - In a survey, almost half the physicians who responded said their perception of Opdivo has changed "significantly" or "very significantly" because of the recent trial failure.

Exclusive: Merck Enters Race For Cancer Drugmaker Medivation - Sources

8/18/2016 10:58 am

(Reuters) Aug 17, 2016 - Merck & Co Inc is one of at least five pharmaceutical companies that submitted indications of interest in buying U.S. cancer drug company Medivation Inc earlier this month, according to people familiar with the matter.

Do the New Merck HPV Ads Guilt-Trip Parents Or Tell Hard Truths? Both.

8/12/2016 11:31 am

(Washington Post/To Your Heath) Aug 11, 2016 - New commercials by HPV vaccine maker Merck, which emphasize the link between the virus and cancer, have sparked charges of parent "shaming."

Trader's Radar: Up, Out and Away They Go in Merck

7/9/2012 04:02 am

[Optionetics] - Trader's Radar: Up, Out and Away They Go in Merck